JP2003514821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514821A5 JP2003514821A5 JP2001538914A JP2001538914A JP2003514821A5 JP 2003514821 A5 JP2003514821 A5 JP 2003514821A5 JP 2001538914 A JP2001538914 A JP 2001538914A JP 2001538914 A JP2001538914 A JP 2001538914A JP 2003514821 A5 JP2003514821 A5 JP 2003514821A5
- Authority
- JP
- Japan
- Prior art keywords
- diseases
- formula
- physiologically acceptable
- hal
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- -1 imidazole compound Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19954707A DE19954707A1 (de) | 1999-11-13 | 1999-11-13 | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
| DE19954707.6 | 1999-11-13 | ||
| PCT/EP2000/010765 WO2001036425A2 (de) | 1999-11-13 | 2000-10-31 | Imidazolverbindungen als phosphodiesterase vii-hemmer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514821A JP2003514821A (ja) | 2003-04-22 |
| JP2003514821A5 true JP2003514821A5 (enExample) | 2007-12-20 |
| JP4819272B2 JP4819272B2 (ja) | 2011-11-24 |
Family
ID=7928973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538914A Expired - Fee Related JP4819272B2 (ja) | 1999-11-13 | 2000-10-31 | ホスホジエステラーゼｖｉｉ阻害剤として用いられるイミダゾール化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6884800B1 (enExample) |
| EP (1) | EP1228073B1 (enExample) |
| JP (1) | JP4819272B2 (enExample) |
| KR (1) | KR20020049051A (enExample) |
| CN (1) | CN1390222A (enExample) |
| AR (1) | AR026421A1 (enExample) |
| AT (1) | ATE245653T1 (enExample) |
| AU (1) | AU775886B2 (enExample) |
| BR (1) | BR0015487A (enExample) |
| CA (1) | CA2391087A1 (enExample) |
| CZ (1) | CZ20021474A3 (enExample) |
| DE (2) | DE19954707A1 (enExample) |
| DK (1) | DK1228073T3 (enExample) |
| ES (1) | ES2200968T3 (enExample) |
| HU (1) | HUP0203422A3 (enExample) |
| MX (1) | MXPA02004728A (enExample) |
| NO (1) | NO20022232D0 (enExample) |
| PL (1) | PL355098A1 (enExample) |
| PT (1) | PT1228073E (enExample) |
| RU (1) | RU2002113759A (enExample) |
| SK (1) | SK6012002A3 (enExample) |
| WO (1) | WO2001036425A2 (enExample) |
| ZA (1) | ZA200204729B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| MX2009010450A (es) * | 2007-03-27 | 2009-11-23 | Omeros Corp | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. |
| DE102007047738A1 (de) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| KR102385359B1 (ko) | 2010-11-08 | 2022-04-11 | 오메로스 코포레이션 | Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료 |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| US11685745B2 (en) | 2017-07-12 | 2023-06-27 | Dart Neuroscience, Llc | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors |
| CA3264513A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2919271A (en) * | 1957-12-05 | 1959-12-29 | Smith Kline French Lab | 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines |
| EP0480939B1 (en) * | 1989-06-09 | 1995-01-25 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
| US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
| ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
-
1999
- 1999-11-13 DE DE19954707A patent/DE19954707A1/de not_active Withdrawn
-
2000
- 2000-10-31 PT PT00975978T patent/PT1228073E/pt unknown
- 2000-10-31 US US10/129,629 patent/US6884800B1/en not_active Expired - Fee Related
- 2000-10-31 CZ CZ20021474A patent/CZ20021474A3/cs unknown
- 2000-10-31 EP EP00975978A patent/EP1228073B1/de not_active Expired - Lifetime
- 2000-10-31 RU RU2002113759/04A patent/RU2002113759A/ru unknown
- 2000-10-31 JP JP2001538914A patent/JP4819272B2/ja not_active Expired - Fee Related
- 2000-10-31 CN CN00815534A patent/CN1390222A/zh active Pending
- 2000-10-31 HU HU0203422A patent/HUP0203422A3/hu unknown
- 2000-10-31 CA CA002391087A patent/CA2391087A1/en not_active Abandoned
- 2000-10-31 AU AU13907/01A patent/AU775886B2/en not_active Ceased
- 2000-10-31 BR BR0015487-3A patent/BR0015487A/pt not_active Application Discontinuation
- 2000-10-31 DK DK00975978T patent/DK1228073T3/da active
- 2000-10-31 AT AT00975978T patent/ATE245653T1/de not_active IP Right Cessation
- 2000-10-31 SK SK601-2002A patent/SK6012002A3/sk unknown
- 2000-10-31 KR KR1020027006131A patent/KR20020049051A/ko not_active Withdrawn
- 2000-10-31 MX MXPA02004728A patent/MXPA02004728A/es not_active Application Discontinuation
- 2000-10-31 PL PL00355098A patent/PL355098A1/xx unknown
- 2000-10-31 ES ES00975978T patent/ES2200968T3/es not_active Expired - Lifetime
- 2000-10-31 DE DE50003036T patent/DE50003036D1/de not_active Expired - Lifetime
- 2000-10-31 WO PCT/EP2000/010765 patent/WO2001036425A2/de not_active Ceased
- 2000-11-10 AR ARP000105929A patent/AR026421A1/es unknown
-
2002
- 2002-05-10 NO NO20022232A patent/NO20022232D0/no not_active Application Discontinuation
- 2002-06-12 ZA ZA200204729A patent/ZA200204729B/en unknown